Sociedad Americana de Hirudoterapia

The role of the insertion loop around tryptophan 148 in tthe activity of thrombin.

Research article published in Biochemistry (1996)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryDesarrollo de fármacosFarmacología salivalDiBella et al. · Biochemistry, 1996

Abstract

Thrombin has trypsin-like specificity for Arg-Xaa and Lys-Xaa peptide bonds; however, it is much more specific than trypsin, cleaving far fewer peptide bonds in macromolecular substrates. To probe the nature of the specificity of thrombin, a mutant has been constructed in which the Trp148 loop of thrombin has been replaced with the same loop of bovine trypsin. This mutant was expressed in Escherichia coli as prethrombin-2(148) using a T7 expression system previously described for wild-type prethrombin-2 [DiBella et al. (1995) J. Biol. Chem. 270, 163-169]. After refolding and purification, prethrombin-2(148) was activated to thrombin(148) with Echis carinatus snake venom. The k(cat)/K(m) for the release of fibrinopeptide A from fibrinogen was 4.5 +/- 0.5 microM(-1)s(-1) for thrombin(148), which was approximately 20% of that of recombinant thrombin (25 +/- 2.0 microM(-1)s(-1)). Thrombin(148) was inhibited less well by hirudin with a K(i) of 500 pM compared to a value of 12 pM determined for recombinant thrombin. The mutant thrombin was also compared to trypsin and wild-type recombinant thrombin for the ability to cleave small peptide substrates. The Michaelis constants (K(m)) were found to be between 5- and 10-fold higher for thrombin(148) relative to wild-type recombinant thrombin, although the catalytic constants (k(cat)) for thrombin(148) and recombinant thrombin remained relatively unchanged for all three substrates. Thrombin(148) had a specificity constant (k(cat)/K(m)) 2-fold higher for the hydrolysis of H-D-phenyalanyl-L- pipecolyl-L-arginine-p-nitroaniline (a thrombin substrate) than that of trypsin. For N-benzoyl-L-isoleucyl-L-glutamylglycyl-L-arginine- p-nitroaniline (a trypsin substrate) and N-carbobenzoxyglycylprolyl-L-arginine-p-nitroaniline (a substrate for both enzymes), the specificity constants for trypsin were 1000- and 16-fold higher, respectively. Although replacement of the Trp(148) loop does not yield an enzyme with more trypsin-like specificity, the Trp(148) loop is important in the substrate binding and specificity of thrombin (on the basis of K(m) and K(i)).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino Acid SequenceAnimalsBase SequenceBinding SitesCattleDNAEnzyme PrecursorsEscherichia coliIn Vitro TechniquesKineticsModels, MolecularMolecular Sequence Data

Resumen

Thrombin has trypsin-like specificity for Arg-Xaa and Lys-Xaa peptide bonds; however, it is much more specific than trypsin, cleaving far fewer peptide bonds in macromolecular substrates. To probe the nature of the specificity of thrombin, a mutant has been constructed in which the Trp148 loop of...

Por qué esto importa para la hirudoterapia

DiBella et al. (1996, Biochemistry) exploraron la especificidad de sustrato de la trombina mediante el diseño de un mutante en el cual el bucle de inserción Trp148 de la trombina fue reemplazado por el bucle correspondiente de la tripsina bovina; el mutante conservó en general una especificidad similar a la de la trombina, pero mostró una cinética alterada y, notablemente, fue inhibido en mucha menor medida por hirudin (Ki ~500 pM) que la trombina recombinante (Ki ~12 pM), lo que implica al bucle Trp148 en la unión y especificidad del sustrato. Para ASH, esta es la bioquímica fundamental detrás de la historia del anticoagulante de la sanguijuela: hirudin, el inhibidor de trombina característico de la sanguijuela medicinal, se utiliza aquí como una sonda molecular, y la marcada pérdida de inhibición con el intercambio del bucle ayuda a mapear cómo hirudin reconoce y bloquea la trombina — la base de la anticoagulación derivada de la sanguijuela. Advertencia honesta: se trata de un estudio de enzimología/ingeniería de proteínas in vitro que utiliza proteínas recombinantes, no de una investigación clínica ni siquiera animal de la hirudoterapia, y los datos de hirudin son un resultado mecanístico en lugar de una evidencia de efecto terapéutico.

Citación

The role of the insertion loop around tryptophan 148 in tthe activity of thrombin.

DiBella et al. · Biochemistry, 1996

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.